Kornimate/medical-research-clean huggingface dataset:
covid-19 pandemic response network

Conditions: COVID-19; SARS-CoV-2; Coronavirus; Influenza -Like Illness; Lower Resp Tract Infection; Upper Resp Tract Infection

Summary: coronavirus disease 19 (covid-19) represents an unprecedented challenge to the operations and population health management efforts of health care systems around the world. the "pandemic research network (prn): duke community health watch" study leverages technology, clinical research, epidemiology, telemedicine, and population health management capabilities to understand how to safely covid-19. the target population is individuals in the duke health region as well as individuals beyond the duke health region who have flu-like symptoms, a viral test order for covid-19, confirmed covid-19, or concern for exposure to covid-19. a subgroup of particular interest within the target population is health care workers (hcw) and families of hcw. community members will enroll in the study electronically and for 28 days will be reminded via email or sms to submit signs and symptoms related to covid-19. participants who report symptoms will be provided information about covid-19 testing (if needed) and established mechanisms to seek care within duke health. instructions for telemedicine and in-person visits, which is available publicly at https://www.dukehealth.org/covid-19-update, will be presented to participants. participants who are unable to report symptoms independently may be contacted via telephone by population health management office (phmo) or clinical events classification (cec) team members. data collected through the "pandemic response network (prn): duke community health watch" study will be used for three objectives. * first, to characterize the epidemiological features of covid-19. specifically, we will have a high-risk subgroup of hcw and families of hcw that we enroll. * second, to develop models that predict deterioration and the need for inpatient care, intensive care, and mechanical ventilation. * third, to develop forecast models to estimate the volume of inpatient and outpatient resources needed to manage a covid-19 population. the primary risk to study participants is loss of protected health information. to address this concern, all data will be stored in duke's redcap instance and the duke protected analytics compute environment (pace).


Eligibility criteria:
inclusion criteria: * flu-like symptoms * a viral test order for covid-19 * confirmed covid-19 * concern for exposure to covid-19 exclusion criteria: - none
frailty in critical care unit's patients

Conditions: CFS

Summary: in the study ,investigator aim to evaluate the frailty syndrome in critically ill patients, in both young and old populations,to determine its imapct on outcome, and impact of icu in fraility


Eligibility criteria:
inclusion criteria: * all icu patients \>18 years exclusion criteria: * age \<18 years
a study of tarceva (erlotinib) in patients with locally advanced or metastatic non-small cell lung cancer (trigger)

Conditions: Non-Squamous Non-Small Cell Lung Cancer

Summary: this single-arm, open-label study evaluated the efficacy and safety of tarceva (erlotinib) in participants with locally advanced or metastatic non-small cell lung cancer. participants received daily oral doses of 150 mg tarceva. the anticipated time on study treatment was 12 months.


Eligibility criteria:
inclusion criteria: * adult patients, \>/=18 years of age * locally advanced or metastatic non-small cell lung cancer * measurable disease according to response evaluation criteria in solid tumors (recist) * eastern cooperative oncology group (ecog) performance status 0-2 * life expectancy over \>/=12 weeks * adequate hematological, liver, or kidney function exclusion criteria: * previous therapy against epidermal growth factor receptor for metastatic disease * treatment with investigational drug during the 3 weeks before enrollment * history of neoplasm * patients with symptomatic cerebral metastases * unstable systemic disease
borderline resectable pancreatic cancer neoadjuvant chemoradiotherapy clinicaltrial-1

Conditions: Pancreatic Cancer

Summary: this study is to investigate whether neoadjuvant chemotherapy plus sbrt results in better outcomes compared with neoadjuvant chemotherapy alone and also compare the efficacy of gemcitabine plus nab-paclitaxel with sbrt and s-1 plus nab-paclitaxel with sbrt.

this research study is a phase ii clinical trial that investigate whether neoadjuvant chemotherapy plus sbrt results in better outcomes compared with neoadjuvant chemotherapy alone and also compare the efficacy of gemcitabine plus nab-paclitaxel with sbrt and s-1 plus nab-paclitaxel with sbrt. it is known that neoadjuvant therapy is vital for improved survival, which has been confirmed in previous studies that neoadjuvant chemotherapy with or without radiotherapy provides superior overall compared with upfront surgery. however, question of whether the addition of radiotherapy to neoadjuvant chemotherapy can improve prognosis compared with chemotherapy alone is a challenging matter. also, no studies have evaluated the efficacy of s-1 as the neoadjuvant chemotherapy regimen for brpc albeit similar prognosis has been found between s-1 and gemcitabine in advanced pancreatic cancer. in this trial, patients with biopsy and radiographically confirmed brpc will be randomly allocated into three groups: neoadjuvant gemcitabine plus nab-paclitaxel, neoadjuvant gemcitabine plus nab-paclitaxel with sbrt and neoadjuvant s-1 plus nab-paclitaxel with sbrt. surgical resection will be performed 3 weeks after sbrt. the primary endpoint is overall survival. the secondary outcomes are progression free survival, pathological complete response rate, r0 resection rate and incidence of adverse effects. if results show the survival benefits of neoadjuvant chemotherapy plus sbrt and similar outcomes between s-1 and gemcitabine, it may provide evidence of clinical practice of this modality for brpc.

Eligibility criteria:
inclusion criteria: * age≥18 years old and ≤80 years old; * histological proven pancreatic adenocarcinoma; * borderline resectable pancreatic cancer proven by imaging examinations via multidisciplinary approaches according to nccn guidelines; * no prior chemotherapy or radiotherapy; * ecog of 0 or 1; * routine blood test: absolute neutrophil count\>1500/mm3, platelet\>100000/mm3; * normal liver function: serum total bilirubin≤2.0mg/dl, alt and ast\<2.5 times of the upper limit of normal value; * normal kidney function: serum creatinine\ 45ml/min; * no severe comorbidities. exclusion criteria: * metastatic pancreatic cancer; * patients who had surgeries, chemotherapy or other treatments before inclusion; * impaired organ functions: heart failure (new york heart association iii-iv), coronary heart disease, myocardial infarction within 6 months, severe cardiac arrhythmia and respiratory failure; * confirmed other cancer within 5 years; * pregnant women or lactating women; * patients enrolled in other clinical trials or incompliant of regular follow up; * patients who did not provide an informed consent.

Keywords: pancreatic cancer neoadjuvant chemotherapy sbrt
uc cohort - the influence of diet on gut microbiotas

Conditions: Ulcerative Colitis

Summary: the purpose of this research is to determine if different diets have different effects on the inflammation in the colon.


Eligibility criteria:
inclusion criteria: 1. adults ≥ 18 years old 2. ability to give informed consent 3. diagnosis of ulcerative colitis 4. moderate uc disease activity defined by a mayo score of \>6 with endoscopic score of 2 5. on a baseline diet characterized by: * fiber intake of \< 15g/day * \> 18% of daily calories from protein exclusion criteria: 1. prior history of gastrointestinal surgeries (except appendectomy and cholecystectomy) 2. use of tobacco products within the past 6 months (since nicotine may affect intestinal permeability) 3. use of nsaids or aspirin and unable or unwilling to stop taking two weeks prior to permeability test and for the duration of the study 4. use of osmotic laxatives and unable or unwilling to stop taking one week prior to permeability test and for the duration of the study 5. use of oral corticosteroids and unable or unwilling to stop use of oral corticosteroids within the previous 2 weeks and for the duration of the study 6. multiple dietary restrictions or unable/unwilling to alter dietary protein or dietary fiber. 7. unwilling to stop ingestion of alcohol and artificial sweeteners such as splenda™ (sucralose), nutrasweet™ (aspartame), sorbitol, xylitol, lactulose, or mannitol 2 days before and during the permeability testing days, e.g. foods to be avoided are sugarless gums or mints and diet beverages 8. unwilling to stop stenuous exercise (running \>5 miles or equivalent) one week prior to the permeability tests 9. bowel preparation for colonoscopy less than one week prior to completion of the first stool kit and permeability test and flexible sigmoidoscopy and upper endoscopy 10. pregnancy or plan to become pregnant during the study time frame 11. vulnerable adult 12. known bleeding disorders or takes medications that increase risk of bleeding from mucosal biopsies 13. use of oral antibiotic(s) within the past 4 weeks (can be enrolled after 4-week washout period) 14. use of commercial probiotic formulations and unwilling to stop for the duration of the study 15. diagnosis of diabetes 16. any other disease(s), condition(s) or habits(s) that would interfere with completion of study, or in the judgment of the investigator would potentially interfere with compliance to this study or would adversely affect study outcomes
artificial intelligence-assisted system in colonoscopy

Conditions: Adenoma Colon Polyp

Summary: in recent years, computer-aided diagnosis system based on artificial intelligence (ai) has been used in colorectal polyp detection. in recent years, computer-aided diagnosis system based on artificial intelligence (ai) has been used in colorectal polyp detection. however, whether ai-assisted can improve the adenoma-detection rate (adr) is inconclusive. this study aims to evaluate the real-world performance of an ai system that combines polyp detection with colonoscopy quality control. this study aims to explore the clinical application value of ai-based polyp detection and quality control function by comparing the data of polyp detection rate and adenoma detection rate in multiple centers with and without ai-assisted colonoscopy in a multicenter, prospective real world study. however, whether ai-assisted can improve the adenoma-detection rate (adr) is inconclusive. this study aims to evaluate the real-world performance of an ai system that combines polyp detection with colonoscopy quality control. this study aims to explore the clinical application value of ai-based polyp detection and quality control function by comparing the data of polyp detection rate and adenoma detection rate in multiple centers with and without ai-assisted colonoscopy in a multicenter, prospective real world study.


Eligibility criteria:
inclusion criteria: 1. age \> 50 years old; 2. required diagnostic colonoscopy, screening colonoscopy, or follow-up colonoscopy; 3. voluntarily sign informed consent; 4. commitment to abide by the study procedures and cooperate with the implementation of the whole process of the study. exclusion criteria: 1. have participated in other clinical trials, signed informed consent and are in the follow-up period of other clinical trials; 2. known polyposis syndrome patients; 3. patients with known ibd; 4. patients considered by the investigators to be unsuitable or unable to undergo complete digestive endoscopy and related examinations; 5. high-risk diseases or other special conditions considered by the investigator to be unsuitable for clinical trial participation.
the effect of liraglutide on pancreatic hormones and its size

Conditions: Obesity

Summary: glucagon-like peptide-1 (glp-1) is a gastrointestinal hormone used to treat type 2 diabetes and severe overweight (liraglutide).the two pancreas enzymes: amylase and lipase are slightly elevated in glp-1 treated compared with placebo-treated individuals. increased levels of these two enzymes (amylase and lipase) are associated with acute inflammation of the pancreas (acute pancreatitis). in humans treated with glp-1 (receptor agonist) there have not been found an increased risk of acute pancreatitis. animal and cell studies have shown that the increased levels of amylase and lipase in the blood are not due to an inflammatory state but adaptive changes (volume increase) of the pancreas. the investigators (professor jens juul holst, professor sten madsbad) want to investigate whether the increased levels of amylase and lipase in the blood of individuals treated with the glp-1 analogue saxenda are due adaptive changes of the pancreas. this will be achieved by measuring amylase and lipase before, during and after treatment with a glp-1 receptor agonist, and at the same time use advanced scanning equipment (pet-mr) from the clinical physiological and nuclear medical department at rigshospitalet, which can determine any volumetric changes in the pancreas with high reproducibility. the scan will be centered on the pancreas, other organs are not evaluated why the study is not designed to detect any malignant findings in the pancreas or other organs.


Eligibility criteria:
inclusion criteria: * bmi ≥ 26 og \< 50 kg/m2 exclusion criteria: * abdominal diameter \>60cm type 1 or type 2 diabetes heart failure or disease statins kidney or liver disease thyroid disease inflammatory bowel disease gastroparesis cancer lung disease psychiatric disease gastric bypass operation previous pancreatitis increased alcoholic consumption familiar incidence of multiple endocrine neoplasia previous treatment with glp-1 (incretin) based medicine pacemaker or other non-mr-compatible devices

Keywords: amylase lipase glp-1
a study observing us patients with hae type i or ii who take icatibant to treat hae attacks

Conditions: Hereditary Angioedema

Summary: patients with hae type i or ii who enroll in the study are asked to complete a patient diary when they experience an hae attack. if icatibant is taken as the first treatment for the attack, the patient diary will ask questions over a 48 hour period after dosing to track the characteristics and severity of the attack along with the patient's level of anxiety.


Eligibility criteria:
inclusion criteria: 1. male or female patients 12 years of age and older 2. diagnosis of hae type i or ii, based on us hereditary angioedema association (haea) database records and/or verbal confirmation from the patient 3. currently using icatibant to treat hae attacks 4. if a patient is receiving long-term prophylactic treatment, they must have been on a stable dose and regimen for at least 3 months prior to the screening visit 5. patient has had at least 2 hae attacks in the 3 months prior to the screening visit, as self-reported verbally by the patient 6. patient is able to read, understand, and complete the ediary 7. patient is willing and able to adhere to all protocol requirements exclusion criteria: 1. any concomitant diagnosis of another form of chronic angioedema, such as acquired c1-inhibitor deficiency, hae with normal c1-inh (previously known as hae type iii), idiopathic angioedema, or angioedema associated with urticaria 2. use of angiotensin-converting enzyme inhibitors 3. participation in any gene therapy treatment or trial for hae 4. participation in any interventional investigational clinical trial within 4 weeks prior to screening 5. any pregnant or breastfeeding patient
mechanisms of change in adolescent pain self-management

Conditions: Chronic Pain; Central Sensitisation; Headache

Summary: the mocas study aims to describe the mechanisms through which sleep deficiency affects youth responses to an online pain self-management intervention over a 6-month period. the study is a single arm trial with repeated measurements using surveys, daily diaries, and actigraphic monitoring.

the study objective is to characterize how sleep deficiency influences youth's ability to engage with, implement, and benefit from pain self-management intervention. the investigators will recruit a cohort of 80 youth, ages 12 to 17 years, with chronic musculoskeletal, head, or abdominal pain into a single arm trial conducted at one site. assessments will occur at baseline, immediately after intervention, and repeated at 3 months post-intervention. mediators will be assessed at mid-treatment (4 weeks). all youth will receive an 8-week internet-delivered pain self-management intervention (webmap). following the recommended common data elements for self-management three self-management processes are measured including patient activation, pain self-efficacy, and self-management skills, and patient-reported outcomes of health (global health, fatigue) and pain (pain symptoms, pain-related disability). positive and negative affect and executive function are assessed as potential mediators. sleep deficiency is comprehensively assessed with subjective measures, daily sleep logs, and ambulatory actigraphy monitoring to measure disrupted sleep, amount of sleep, sleep quality, and insomnia symptoms.

Eligibility criteria:
inclusion criteria: * 12-17 years old * has chronic pain (for at least 3 months) * has internet access/email address exclusion criteria: * diagnosis of a serious, comorbid health condition (e.g. cancer, arthritis, cystic fibrosis, lupus, etc.) * parent/adolescent doesn't speak english * active psychosis/suicidal ideation * currently taking stimulating medications * diagnosed sleep disorder (sleep apnea or narcolepsy) * severe cognitive impairment/unable to read at 5th grade level or complete surveys independently

Keywords: chronic pain internet intervention pain management cbt adolescent sleep
hpi effect in robotic urological surgery on aki

Conditions: Prostate Cancer; Renal Cancer; Urologic Diseases

Summary: it is a single-center randomized controlled trial that aims to figure out the effect of the hypotension prediction index (hpi) on the prevention of acute kidney injury (aki) after robot-assisted urological surgery. the primary hypothesis is that hpi software guidance prevents postoperative aki by reducing the duration and severity of intraoperative hypotension (ioh).


Eligibility criteria:
inclusion criteria: * age ≧ 19 * patients undergoing robot-assisted urological surgery exclusion criteria: * unable to voluntarily give consent * unable to use both radial arteries due to such reasons: prior surgery on the radial artery, breast cancer history with axillary ln dissection, av fistula for renal replacement therapy, or abnormal allen's test.

Keywords: robotic
effects of sulfur water and mud therapy on serotonin activity and biochemical parameters in patients' osteoarthrosis

Conditions: Osteoarthritis of Multiple Joints

Summary: this study is to examine the effects of sulfur bath and mud therapy on serotonin levels and other biochemical parameters in the blood of the osteoarthritis patients, as well as water the application of exercise in water effects the results we receive.

sulfur baths and mud packs are known to have a positive effect in patients with osteoarthritis (oa). oa is a chronic degenerative disease accompanied by a constant pain that often leads to changes in the mood of patients. over the last few decades, numerous articles reported various beneficial effects of sulfur water and peloid therapeutic applications. serotonin is one of the important neurotransmitters that have numerous functions such as regulation of body temperature, sleep, appetite, while its main function is reflected in controling of depression. the aim of this study is to examine the effects of sulfur bath and mud therapy on serotonin levels and other biochemical parameters in the blood of the oa patients, as well as whether the application of exercise in water effects the results we receive. randomized controlled study included patients with hip and/or knee oa both sexes, randomized into two groups. the first group patients underwent sulfur balneotherapy and mud pack therapy. patients in the second group had sulfur balneotherapy, mud pack therapy and exercise in hygienic water. the duration of spa therapy program was 12 days. serotonin values, parameters of complete blood count, lipid status and inflammatory markers were analyzed before and after the therapy. this study is expected to be another contribution to existing evidence and shed light on the mechanisms of beneficial effects of balneotherapy and mud therapy and whether addition underwater exercise would have extra therapeutic effects.

Eligibility criteria:
inclusion criteria: 1. ages of 50 - 65 , both sexes 2. patients diagnosed with hip and / or knee oa without having used balneotherapy in the previous year 3. patients who have not changed their medication in the last 2 months 4. patients who have not received injections into the hip and / or knee joint in the last 6 months (prp, diprofos...) exclusion criteria: 1. secondary hip and / or knee oa 2. patients with moa inhibitors, selective serotonin inhibitors, morphine, lithium and methyldopa in therapy 3. visible disruption of hip and / or knee joint structures 4. treatment of malignancy 5. diseases of the heart, lungs, decompensated conditions of other organs, infections, active bleeding 6. severe hip and / or knee joint injuries, fractures, and previous surgical procedures 7. physical therapy, balneotherapy back one year

Keywords: osteoarthritis balneotherapy mud therapy sulfuric water serotonin
to explore cognitive neural mechanism of autoimmune encephalitis by using neuropsychological tests and multi-modal mri

Conditions: Cognitive Impairment; Autoimmune Encephalitis

Summary: most of patients with autoimmune encephalitis are left with permanent cognitive deficits of varying severity. the patients' life and career would be affected definitely by cognitive deficits. recently, more and more clinical physician have begun to focus on cognitive impairment of patients with autoimmune encephalitis. generally, the outcome was measured by the modified rankin scale (mrs). however, the mrs are commonly used to evaluate the degree of disability or dependence in the daily activities of the patients suffering from a stroke and cognition function were minimally evaluated in this scale. it is crucial to adopt detailed cognition tools to study the long-term cognitive outcomes and as an indicator of overall curative effect judgment in autoimmune encephalitis. currently, only early immunotherapy is uniformly and consistently considered to produce favorable cognitive outcomes. however, studies concerning the association of second-line immunotherapy with cognitive outcomes have been scarce and have shown conflicting results regarding autoimmune encephalitis. hence, the goal of this study was to explore cognitive neural mechanism of autoimmune encephalitis by using neuropsychological tests and multi-mode mris.

the goal of this study was to explore cognitive neural mechanism of different types of autoimmune encephalitis by using neuropsychological tests and multi-mode mris. neuropsychological tests involves the assessments of different cognitive domains. and multi-mode mris contains resting-fmri, dti and task-related fmri.

Eligibility criteria:
inclusion criteria: diagnosis was established in all patients based on characteristic clinical presentation and detection of immunoglobulin g (igg) antibodies. - exclusion criteria: 1. age \>60 years or \<16 years 2. notable lesions, such as tumors, scars, or vascular malformations, on brain mri 3. a history of other neuropsychiatric disorders. -

Keywords: episodic memory executive control fmri